The attraction of CSL is the fact that it could do a script deal that would let existing AVX shareholders enjoy the upside of commercialisation. On that basis, they could probably get away with a lower offer than an O/S pharma co.
AVX Price at posting:
8.8¢ Sentiment: Hold Disclosure: Held